glp 1 parkinson's disease and neuroprotection Repurposing GLP-1 Receptor Agonists for Disease: Current Evidence Future Opportunities | Pharmaceutical Medicine The glucagon-like peptide 1 (GLP)
Description
GLP-1 therapies have revolutionised the management of type 2 diabetes and obesity
If managing type 2 diabetes, GLP-1s are typically continued long-term to maintain blood sugar control and reduce cardiovascular risks
Institutions such as PAHO [6] and WHO, through its Controlling the Global Obesity Epidemic initiative [7], are calling for coordinated action
Sanchez and our team can explain the process and help you take the next step
Recommended by professors from Stanford University School of Medicine
